Amplia Therapeutics Ltd. (AU:ATX)
ASX:ATX
Want to see AU:ATX full AI Analyst Report?
ATX Stock Chart & Stats
AU$0.14
<AU$0.01(2.33%)
At close: 4:00 PM EST
AU$0.14
<AU$0.01(2.33%)
Day’s Range― - ―
52-Week RangeAU$0.05 - AU$0.43
Previous CloseN/A
Volume274.48K
Average Volume (3M)525.22K
Market Cap
AU$68.01M
Enterprise ValueAU$41.75M
Total Cash (Recent Filing)AU$27.85M
Total Debt (Recent Filing)AU$341.11K
Price to Earnings (P/E)―
Beta0.19
Next Earnings
Nov 25, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding513,312,000
10 Day Avg. Volume444,673
30 Day Avg. Volume525,217
Financial Highlights & Ratios
PEG Ratio0.61
Price to Book (P/B)2.80
Price to Sales (P/S)0.00
P/FCF Ratio-12.59
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.02
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Equity-backed Balance SheetA sizable equity cushion and low leverage materially lower near-term solvency risk and reduce refinancing pressure. This provides durable financial flexibility to fund clinical programs, pursue partnerships or absorb delays over the next several quarters without immediate liquidity distress.
Proprietary FAK-targeted TherapeuticsA focused, proprietary approach to the FAK pathway creates a clear scientific differentiation and IP-driven moat. Targeting substantial unmet needs in cancer and fibrosis supports long-term partner interest, licensing potential, and a defensible R&D strategy that can sustain value creation over multiple development cycles.
Partnership/licensing Revenue ModelAn asset-light commercial model emphasizing partnerships and milestones reduces the need for immediate internal commercialization scale. Structurally, this can provide non-dilutive funding, de-risk late-stage costs, and align incentives with larger partners to advance programs without requiring full in-house sales infrastructure.
Bears Say
Revenue Deterioration To ZeroA complete loss of revenue is a durable red flag for commercial traction and cash inflows. Absent recurring revenues, the company is more dependent on financing or milestone deals, which increases funding risk and undermines evidence of market demand or commercial viability over the medium term.
Worsening Cash Burn And Negative Cash FlowConsistent negative operating and free cash flow with accelerating burn materially shortens runway and raises dilution risk. Even with equity cushion, sustained cash outflows constrain R&D pacing and force reliance on external funding or partnerships to progress clinical milestones over the next several quarters.
Very Small Operating Scale Increases Execution RiskAn effectively single-person operating base signals limited internal capacity to manage trials, regulatory interactions, and commercialization tasks. This structural constraint increases dependency on external partners, raises coordination risk, and can slow program execution and decision-making over time.
Amplia Therapeutics News
ATX FAQ
What was Amplia Therapeutics Ltd.’s price range in the past 12 months?
Amplia Therapeutics Ltd. lowest share price was AU$0.05 and its highest was AU$0.42 in the past 12 months.
What is Amplia Therapeutics Ltd.’s market cap?
Amplia Therapeutics Ltd.’s market cap is AU$68.01M.
When is Amplia Therapeutics Ltd.’s upcoming earnings report date?
Amplia Therapeutics Ltd.’s upcoming earnings report date is Nov 25, 2026 which is in 173 days.
How were Amplia Therapeutics Ltd.’s earnings last quarter?
Amplia Therapeutics Ltd. released its earnings results on May 29, 2026. The company reported -AU$0.007 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.007.
Is Amplia Therapeutics Ltd. overvalued?
According to Wall Street analysts Amplia Therapeutics Ltd.’s price is currently Overvalued.
Does Amplia Therapeutics Ltd. pay dividends?
Amplia Therapeutics Ltd. does not currently pay dividends.
What is Amplia Therapeutics Ltd.’s EPS estimate?
Amplia Therapeutics Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Amplia Therapeutics Ltd. have?
Amplia Therapeutics Ltd. has 513,312,000 shares outstanding.
What happened to Amplia Therapeutics Ltd.’s price movement after its last earnings report?
Amplia Therapeutics Ltd. reported an EPS of -AU$0.007 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Amplia Therapeutics Ltd.?
Currently, no hedge funds are holding shares in AU:ATX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Amplia Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
66.66%
12-Months-Change
Fundamentals
Return on Equity
-24.81%
Trailing 12-Months
Asset Growth
199.58%
Trailing 12-Months
Company Description
Amplia Therapeutics Ltd.
Amplia Therapeutics (ATX) is a biotechnology company focused on developing innovative therapies for the treatment of fibrotic diseases and cancer. The company specializes in the discovery and development of small molecule drugs that target the underlying biological processes driving these conditions. Amplia's core products include its lead drug candidate, which is designed to inhibit specific pathways involved in fibrosis, thereby offering potential benefits for patients suffering from these debilitating diseases.
Technical Analysis
Tryptamine Therapeutics
―
Neuren Pharmaceuticals Limited
―
Paradigm Biopharmaceuticals
―
Alterity Therapeutics
―
Zelira Therapeutics
―
Options Prices
Currently, No data available
---